DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ad354f/fda_approves_zytig) has announced the addition of GlobalData 's new report "FDA Approves Zytiga (Abiraterone Acetate) for the Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer" to their offering.
It has been an exciting year for prostate cancer therapeutics. On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prostate cancer (CPRC) following failed Taxotere (docetaxel) therapy. This comes after the approval of three molecules for the treatment of prostate cancer in 2010, Jevtana (cabazitaxel) from Sanofi-Aventis, Provenge (sipuleucel-T, a cancer vaccine) and Xgeva (denosumab). These were the first molecules to gain approval since Taxotere, an anti-mitotic chemotherapy, in 2006.
Scope
Zytiga is produced by Centocor Ortho Biotech, a subsidiary of Johnson and Johnson (J&J). It is not considered to be chemotherapy but is instead a hormone treatment. In the body, Zytiga is converted into an androgen biosynthesis inhibitor that acts on 17 a-hydroxylase/C17,20-lyase (CYP17) and consequently reduces testosterone. Testosterone encourages the progression of prostate cancer. This is more comprehensive than other androgen-reducing therapies as it acts on the production of androgens in the testes, adrenal gland and the prostate tissue itself rather than just those produced in the testes.
Reasons to buy
Impact analysis of approval of Zytiga (Abiraterone Acetate)as a Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer
Key Topics Covered:
1 Tables of Contents
2 Summary
3 Prostate Cancer Overview
3.1 Disease Overview
3.2 Epidemiology
3.3 Current Therapy Options
3.4 Unmet Need
3.5 Drivers and Barriers
3.5.1 Drivers
3.5.2 Barriers
3.6 Zytiga
3.6.1 COU-AA-301 Clinical Trial Details
3.6.2 Dosage and Pricing of Zytiga
3.7 Prostate Cancer Market
4 Appendix
For more information visit http://www.researchandmarkets.com/research/ad354f/fda_approves_zytig
CONTACT:
Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS:
INDUSTRY KEYWORDS: Health Pharmaceutical FDA
MEDIA:
| Logo |